Cingulate (CING) Competitors $4.10 0.00 (0.00%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends CING vs. FBIO, ITRM, CELU, CASI, VTVT, KZR, PRLD, XCUR, BIVI, and RFLShould you be buying Cingulate stock or one of its competitors? The main competitors of Cingulate include Fortress Biotech (FBIO), Iterum Therapeutics (ITRM), Celularity (CELU), CASI Pharmaceuticals (CASI), vTv Therapeutics (VTVT), Kezar Life Sciences (KZR), Prelude Therapeutics (PRLD), Exicure (XCUR), BioVie (BIVI), and Rafael (RFL). These companies are all part of the "pharmaceutical preparations" industry. Cingulate vs. Fortress Biotech Iterum Therapeutics Celularity CASI Pharmaceuticals vTv Therapeutics Kezar Life Sciences Prelude Therapeutics Exicure BioVie Rafael Cingulate (NASDAQ:CING) and Fortress Biotech (NASDAQ:FBIO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations, valuation and community ranking. Does the MarketBeat Community prefer CING or FBIO? Fortress Biotech received 320 more outperform votes than Cingulate when rated by MarketBeat users. However, 70.00% of users gave Cingulate an outperform vote while only 63.62% of users gave Fortress Biotech an outperform vote. CompanyUnderperformOutperformCingulateOutperform Votes770.00% Underperform Votes330.00% Fortress BiotechOutperform Votes32763.62% Underperform Votes18736.38% Does the media refer more to CING or FBIO? In the previous week, Fortress Biotech's average media sentiment score of 0.38 beat Cingulate's score of 0.00 indicating that Fortress Biotech is being referred to more favorably in the news media. Company Overall Sentiment Cingulate Neutral Fortress Biotech Neutral Which has higher valuation & earnings, CING or FBIO? Cingulate has higher earnings, but lower revenue than Fortress Biotech. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCingulateN/AN/A-$23.53MN/AN/AFortress Biotech$62.50M0.76-$60.64M-$3.05-0.56 Do analysts prefer CING or FBIO? Cingulate currently has a consensus target price of $8.00, indicating a potential upside of 95.12%. Fortress Biotech has a consensus target price of $13.67, indicating a potential upside of 694.57%. Given Fortress Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Fortress Biotech is more favorable than Cingulate.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cingulate 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67Fortress Biotech 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals hold more shares of CING or FBIO? 41.3% of Cingulate shares are owned by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are owned by institutional investors. 17.1% of Cingulate shares are owned by insiders. Comparatively, 33.4% of Fortress Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is CING or FBIO more profitable? Cingulate has a net margin of 0.00% compared to Fortress Biotech's net margin of -84.53%. Fortress Biotech's return on equity of 0.00% beat Cingulate's return on equity.Company Net Margins Return on Equity Return on Assets CingulateN/A -570.20% -236.15% Fortress Biotech -84.53%N/A -34.93% Which has more risk and volatility, CING or FBIO? Cingulate has a beta of -0.78, indicating that its stock price is 178% less volatile than the S&P 500. Comparatively, Fortress Biotech has a beta of 1.7, indicating that its stock price is 70% more volatile than the S&P 500. SummaryFortress Biotech beats Cingulate on 11 of the 14 factors compared between the two stocks. Ad Banyan Hill PublishingDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001." I put all the details together for you here — but please hurry. Get Cingulate News Delivered to You Automatically Sign up to receive the latest news and ratings for CING and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CING vs. The Competition Export to ExcelMetricCingulatePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.17M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E RatioN/A10.5989.9717.18Price / SalesN/A195.801,116.21116.99Price / CashN/A57.1642.8937.86Price / Book-0.065.094.784.78Net Income-$23.53M$151.83M$120.23M$225.60M7 Day Performance-2.61%-2.13%-1.92%-1.23%1 Month Performance-12.02%-3.10%11.49%3.36%1 Year Performance100.00%11.54%30.57%16.60% Cingulate Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CINGCingulate2.058 of 5 stars$4.10flat$8.00+95.1%+90.7%$13.17MN/A0.0013FBIOFortress Biotech3.1454 of 5 stars$1.87-3.6%$13.67+630.8%-27.1%$51.62M$62.50M-0.63186ITRMIterum Therapeutics2.0497 of 5 stars$1.88+4.2%$5.00+166.7%+6.0%$51.59MN/A-0.9410CELUCelularityN/A$2.29+3.2%N/A+36.9%$50.35M$48.20M0.00220CASICASI Pharmaceuticals3.083 of 5 stars$3.18+2.3%$6.00+88.7%-59.2%$49.17M$22.06M-1.39180VTVTvTv Therapeutics2.0038 of 5 stars$15.30+1.8%$35.00+128.8%+70.4%$48.81M$2.02M-3.329Gap UpKZRKezar Life Sciences3.7081 of 5 stars$6.62-1.9%$40.50+511.8%-25.0%$48.30M$7M-0.5160Analyst ForecastNews CoveragePRLDPrelude Therapeutics2.9348 of 5 stars$0.88+9.5%$4.00+356.6%-67.3%$48.21MN/A-0.52120News CoveragePositive NewsGap UpHigh Trading VolumeXCURExicure0.8904 of 5 stars$18.40+6.3%N/A+2,901.6%$48.02M$28.83M-9.2750News CoverageGap UpBIVIBioVie1.1623 of 5 stars$2.62-0.8%$3.00+14.5%+47.3%$46.55MN/A-0.2310RFLRafael0.7393 of 5 stars$1.88flatN/A+6.6%$46.38M$640,000.00-1.1313Gap Down Related Companies and Tools Related Companies Fortress Biotech Competitors Iterum Therapeutics Competitors Celularity Competitors CASI Pharmaceuticals Competitors vTv Therapeutics Competitors Kezar Life Sciences Competitors Prelude Therapeutics Competitors Exicure Competitors BioVie Competitors Rafael Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CING) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cingulate Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cingulate With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CING Stock Alerts